Relugolix comment watch save

  • FDA APPROVAL DATE: 12/18/2020
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    CYP3A inducers, Erythromycin, P-gp inhibitors, Rifampin
  • PREGNANCY: Relugolix can cause fetal harm. Advise males with female partners of reproductive potential to use effective contraception.

Androgen deprivation therapy, such as Relugolix, may prolong the QT/QTc interval.

Please login to view the rest of this drug profile.

Page last updated 08/21/2024

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top